Clinical Trials · NCT06704763
A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy Participants
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 27
- Start date
- Dec 2024
- Locations
- 1 site, United States
- Primary endpoint
- Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of Orforglipron